A retired CEO and executive from Vero Beach, Florida, Quinton Oswald started his career in biotech general management in the 1970s. Thirteen years before retiring in Vero Beach, Quinton Oswald served as the vice president and Business Unit Head (including ophthalmology) of Genentech Inc., a biotechnological company based in California.
In July 2023, Genentech announced positive results in the effectiveness of Vabysmo, a drug that treats vision loss. The company presented its findings at the July 2023 American Society of Retina Specialist Annual Meeting.
According to the press release, the drug shows promise in treating two conditions: wet, age-related macular degeneration (AMD) and diabetic macular edema (DME). The findings suggest that Vabysmo might reduce vision-impacting fibrosis better than the leading drug, Aflibercept. Further, the press release mentioned the drug’s ability to reduce the length of the condition.
Seventy countries have approved the drug to treat AMD and DME as of the July 2023 press release. Studies show that AMD and DME affect more than two million people in the United States and 40 million globally.
